MNKD Has Plenty of Room Ahead

[mnholdem]

Biotechnology
MannKind (MNKD) Stock Has Plenty Of Room Ahead

Excerpt:

The Takeaway

The takeaway here is a simple one. With recent news from MannKind with regard to its agreement with United, the company is now on stronger financial footing and the value of technosphere has been validated in a big way. In the short run, things are looking pretty peachy. However, if you get in on this one, make sure to watch the financial data closely. With a relatively high cash burn, the new funds will only keep the company alive into the second or third quarter of next year. After that there may be cause for concern. Nonetheless, in the short term, there could be a big opportunity here and if the company plays its cards right in the long term, the opportunity could quickly grow from big to MASSIVE.

Source: www.google.com/amp/iwatchmarkets.com/mannkind-mnkd-stock-has-plenty-of-room-ahead/534/amp/

[mytakeonit]

Interesting that still no mention of international sales.

[mango]

Great article, I can tell Brandi believes in MannKind because of the choice of words and the Phoenix theme.

Wonder if she knows about MNKD ProBoards?

[sportsrancho]

finance.yahoo.com/news/development-partnership-could-pay-off-205656224.html

[sayhey24]

Sports - please, please, please, stop with all the great news! My head is going to explode.

As an official and long standing MNKD cult member I am only conditioned to expect bad news.

[mnholdem]

Sept 6, 2018 5:44:28 GMT -5 sportsrancho said:

finance.yahoo.com/news/development-partnership-could-pay-off-205656224.html

Excerpts:

Fair Value on MNKD Stock

Only one analyst offered a price target on MannKind stock, setting a $4 price target, or over 90% upside. Though it is too early to predict, the company has a better chance of moving higher not just on the commercialization of treprostinil, but also because it could develop new products with the additional $10 million it has available for spending on research and development.

Using a 10-year DCF Revenue Exit model, at a discount rate of between 12-14%, MNKD shares are worth between $2.05 to $2.73 with an average fair value of around $2.40. This assumes MannKind’s revenue will grow in the range of 20-25% starting in FY 2019. Readers may enter their own assumptions on finbox.io with this link.

Bottom Line on MannKind

Speculative investors may chase MNKD stock and still make money despite the run-up of over 80%. Those who prefer to wait for a pullback may now expect a brighter future for this biotech company.

Disclosure: The author does not own shares in any of the companies mentioned.

[boca1girl]

The iwatch article is much more positive than the yahoo article but that should have been expected based on yahoo’s track record with MNKD.